Cyclosporine and anti-interleukin 2 receptor monoclonal antibody therapy suppress accelerated rejection of rat cardiac allografts through different effector mechanisms.

Monoclonal anti-tumor necrosis factor-alpha antibody treatment of rat cardiac allografts: synergism with low-dose cyclosporine and immunohistological studies.

Evidence that therapeutic strategies targeted at CD4+ cells modulate accelerated rejection of cardiac allografts in sensitized rats by different mechanisms.

Effector mechanisms of rejection.

Accelerated rejection of allografted rat liver perfused with anti-ICAM-1 monoclonal antibody.

Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts.

The cannabinoid receptor 2 is involved in acute rejection of cardiac allografts.

A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma.

In vitro correlates of in vivo therapy with cyclosporine to immunosuppress rejection of heterotopic rat cardiac allografts across strong (RT-1) plus weak (non-RT-1) histocompatibility differences.

Anti-huCD20 antibody therapy for antibody-mediated rejection of renal allografts in a mouse model.

Survival, function, morphology and serological aspects of rat renal allografts. Effect of short-term treatment with cyclosporine A, anti-CD4 and anti-interleukin-2 receptor monoclonal antibodies.

Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.

Graft-derived CCL2 increases graft injury during antibody-mediated rejection of cardiac allografts.

Reversal of graft rejection with monoclonal anti-interleukin-2 receptor.

Monoclonal antibody technology for cyclosporine monitoring.

A monoclonal antibody to the interleukin-2 receptor enhances the survival of neural allografts: a time-course study.

Rapidly proliferative arteriopathy in cyclosporin-induced permanently surviving rat cardiac allografts simulating chronic vascular rejection.

Rat tumour allografts evoke anaphylactic antibody responses.

Anti-rejection therapy in renal transplantation: Use of the monoclonal antibody OKT3.

Effects of prostaglandin E2 (PGE2) and drugs affecting PGE2 degradation on acute rejection of rat cardiac allografts.

Monoclonal antibody therapy of cancer.

In situ effector mechanisms in rat kidney allograft rejection. II. Heterogeneity of the effector cells in the inflammatory infiltrate vs that in the spleen of the recipient rat.

Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.

Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms.

Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms.

Suggest Documents

Monoclonal anti-tumor necrosis factor-alpha antibody treatment of rat cardiac allografts: synergism with low-dose cyclosporine and immunohistological studies.

Evidence that therapeutic strategies targeted at CD4+ cells modulate accelerated rejection of cardiac allografts in sensitized rats by different mechanisms.

Effector mechanisms of rejection.

Accelerated rejection of allografted rat liver perfused with anti-ICAM-1 monoclonal antibody.

Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts.

The cannabinoid receptor 2 is involved in acute rejection of cardiac allografts.

A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma.

In vitro correlates of in vivo therapy with cyclosporine to immunosuppress rejection of heterotopic rat cardiac allografts across strong (RT-1) plus weak (non-RT-1) histocompatibility differences.

Anti-huCD20 antibody therapy for antibody-mediated rejection of renal allografts in a mouse model.

Survival, function, morphology and serological aspects of rat renal allografts. Effect of short-term treatment with cyclosporine A, anti-CD4 and anti-interleukin-2 receptor monoclonal antibodies.

Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts.

Graft-derived CCL2 increases graft injury during antibody-mediated rejection of cardiac allografts.

Reversal of graft rejection with monoclonal anti-interleukin-2 receptor.

Monoclonal antibody technology for cyclosporine monitoring.

A monoclonal antibody to the interleukin-2 receptor enhances the survival of neural allografts: a time-course study.

Rapidly proliferative arteriopathy in cyclosporin-induced permanently surviving rat cardiac allografts simulating chronic vascular rejection.

Rat tumour allografts evoke anaphylactic antibody responses.

Anti-rejection therapy in renal transplantation: Use of the monoclonal antibody OKT3.

Effects of prostaglandin E2 (PGE2) and drugs affecting PGE2 degradation on acute rejection of rat cardiac allografts.

Monoclonal antibody therapy of cancer.

In situ effector mechanisms in rat kidney allograft rejection. II. Heterogeneity of the effector cells in the inflammatory infiltrate vs that in the spleen of the recipient rat.

Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.

Epithelial splicing regulatory proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms.

Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms.

Cyclosporine and anti-interleukin 2 receptor monoclonal antibody therapy suppress accelerated rejection of rat cardiac allografts through different effector mechanisms.

Recommend Documents

Follow Us